ERSP refers Moxxor, Siglas to FTC
This article was originally published in The Tan Sheet
The Electronic Retailing Self-Regulation Program refers Moxxor, the omega-3 dietary supplement, to the Federal Trade Commission after the product's manufacturer of the same name failed to respond to an inquiry about its product, ERSP says Oct. 27. ERSP conducted a review of the firm's online advertising after receiving an anonymous complaint, and later requested substantiation for performance, endorsement, superiority and testimonial claims. ERSP also refers Siglas Inc. to the FTC for not substantiating performance and exclusivity claims for the Sauna Twin Multi-Lipo Reductor. Siglas failed to submit a "substantive response" to ERSP despite multiple requests and a 10-day deadline extension, ERSP said in a separate Oct. 27 release
You may also be interested in...
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.